Anaspec has released isoform-specific PKD1 and PKD2 antibodies, which were raised using sequences from the C-terminus of PKD1 and PKD2.
Protein kinase D (PKD), a serine/threonine kinase originally described as a novel PKC family member and termed PKCm, belongs to the calcium calmodulin super-family of kinases.
Three mammalian isoforms have so far been described: PKD1/PKCm, PKD2 and PKD3/PKCn.
These isoforms show a high degree of homology, especially in their catalytic domain.
PKDs are major targets for tumour-promoting phorbol esters.
They are activated via G protein-coupled receptors (GPCRs) and their activation is also dependent on PKC activation.
PKDs have been implicated in numerous cellular functions, including signal transduction and cell survival, migration, differentiation and proliferation.
They are important regulators of secretory transport at the trans-golgi network.
PKD1 is involved in the regulation of Golgi function, cell proliferation and apoptosis and it mediates oxidative stress signalling, regulating cellular detoxification and survival.
PKD2 has been found to phosphorylate histone H1 more efficiently than aldolase in vitro.
Anti-PKD1 only recognises PKD1 and not PKD2 and PKD3.
Anti-PKD2 only recognises PKD2 and not PKD1 or PKD3.
